Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940059 | 1.00 | CYP2A6 (0.53) | CYP2A6AXLIMPDH2ALDH1A1RAB9A | |
| SCHEMBL658960 | 0.83 | AXL (0.42) | CYP2A6AXLIMPDH2ALDH1A1CCNT1 | |
| SCHEMBL1006461 | 0.77 | CYP2A6 (0.56) | CYP2A6AXLIMPDH2ALDH1A1POLB | |
| SCHEMBL28913407 | 0.77 | CYP2A6 (0.51) | CYP2A6ALDH1A1RAB9ASMN1; SMN2PIM1 | |
| SCHEMBL31167180 | 0.77 | CYP2A6 (0.56) | CYP2A6AXLIMPDH2ALDH1A1POLB | |
| SCHEMBL14438020 | 0.77 | CYP2A6 (0.51) | CYP2A6ALDH1A1RAB9ASMN1; SMN2CYP19A1 | |
| SCHEMBL31751996 | 0.76 | CYP2A6 (0.47) | CYP2A6ALDH1A1RAB9ASMN1; SMN2CHUK | |
| SCHEMBL18878988 | 0.72 | CYP2A6 (0.47) | CYP2A6ALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL194929 | 0.72 | CYP2A6 (0.47) | CYP2A6ALDH1A1RAB9ASMN1; SMN2CYP19A1 | |
| SCHEMBL10285458 | 0.72 | CYP2A6 (0.47) | CYP2A6ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| EP-4408845-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| WO-2015076600-A1 | NOVEL LIGHT EMISSION COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 주식회사 동진쎄미켐 | 2015-05-28 | — | — | WO | disclosed |
| WO-2014031784-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | ALIOS BIOPHARMA, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| US-4902694-A | TREATING CONGESTIVE HEART FAILURE | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | CYP2A6 4205/4885AXL 4536/4885IMPDH2 1725/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | CYP2A6 4442/4885AXL 4461/4885IMPDH2 1491/4885 |
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | CYP2A6 1079/4885AXL 1429/4885IMPDH2 1995/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | CYP2A6 4345/4885AXL 4017/4885IMPDH2 351/4885 |
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | CYP2A6 931/4885AXL 4218/4885IMPDH2 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.